Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antidepressants in panic disorder

J W Jefferson1

  • 1Department of Psychiatry, University of Wisconsin Medical School, Madison, USA.

The Journal of Clinical Psychiatry
|January 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Do subtle neurological impairments predict treatment resistance to clomipramine in children and adolescents with obsessive-compulsive disorder?

Journal of child and adolescent psychopharmacology·2009
Same author

Mitrazapine-associated palinopsia.

The Journal of clinical psychiatry·2001
Same author

New technologies to improve clinical trials.

Journal of clinical psychopharmacology·2001
Same author

Clozapine and pulmonary embolus.

The American journal of psychiatry·2001
Same author

Benzodiazepines and anticonvulsants for social phobia (social anxiety disorder).

The Journal of clinical psychiatry·2001
Same author

Mood stabilizers during breastfeeding: a review.

The Journal of clinical psychiatry·2000
Same journal

Major Depressive Disorder and PTSD Treatment Outcome in Interpersonal Psychotherapy and Prolonged Exposure.

The Journal of clinical psychiatry·2026
Same journal

Psychiatrists and Medical Aid in Dying: Entering Uncharted Waters.

The Journal of clinical psychiatry·2026
Same journal

Mind and Metabolism in Crisis: US Mortality Involving Obesity and Psychiatric Disorders-Trends, Disparities, and ARIMA Projections.

The Journal of clinical psychiatry·2026
Same journal

Generative AI for the Clinical Psychopharmacologist: Is It Ready for Prime Time?

The Journal of clinical psychiatry·2026
Same journal

Posttrauma Benzodiazepine Use and Subsequent PTSD: A Population-Wide Analysis Following Extreme Traumatic Exposure.

The Journal of clinical psychiatry·2026
Same journal

The Challenges of PTSD Prevention: Placing Benzodiazepine Use in Context.

The Journal of clinical psychiatry·2026
See all related articles

Antidepressants like SSRIs are increasingly preferred for panic disorder treatment. While MAOIs are potent, their side effects are limiting, and newer data support SSRI efficacy.

Area of Science:

  • Pharmacology
  • Psychiatry
  • Clinical Medicine

Background:

  • Antidepressants have been a cornerstone in treating panic disorder since their introduction.
  • Various classes, including Tricyclic Antidepressants (TCAs), Monoamine Oxidase Inhibitors (MAOIs), and Selective Serotonin Reuptake Inhibitors (SSRIs), have been investigated.

Purpose of the Study:

  • To review the efficacy and clinical use of different antidepressant classes in managing panic disorder.
  • To highlight the emerging data supporting the first-line use of SSRIs for panic disorder.

Main Methods:

  • Review of existing literature on antidepressant use in panic disorder.
  • Analysis of clinical trial data and expert opinions on different antidepressant classes.

Main Results:

Related Experiment Videos

  • Monoamine Oxidase Inhibitors (MAOIs) are considered potent but have significant side effects limiting their use.
  • Tricyclic antidepressants (TCAs) like imipramine and clomipramine are established treatments.
  • Emerging data increasingly support Selective Serotonin Reuptake Inhibitors (SSRIs) as a preferred first-line treatment.

Conclusions:

  • Selective Serotonin Reuptake Inhibitors (SSRIs) are becoming the preferred first-line pharmacotherapy for panic disorder.
  • The choice of antidepressant for panic disorder balances efficacy with tolerability and side effect profiles.